Status:
COMPLETED
Prospective Epidemiological Study Of The Prevalence Of HLA-B*5701
Lead Sponsor:
ViiV Healthcare
Collaborating Sponsors:
GlaxoSmithKline
Conditions:
Infection, Human Immunodeficiency Virus
Eligibility:
All Genders
18+ years
Brief Summary
This is a study to determine the prevalence of a genetic marker, HLA-B5701, in the UK population. HLA-B\*5701 has been strongly associated with the risk of an allergic reaction to a HIV medicine, Abac...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- HIV-1 infected patients over 18 years of age
- Patient willing \& able to understand and provide written informed consent
- Exclusion criteria:
- None
Exclusion
Key Trial Info
Start Date :
March 20 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 10 2007
Estimated Enrollment :
1502 Patients enrolled
Trial Details
Trial ID
NCT00453440
Start Date
March 20 2007
End Date
August 10 2007
Last Update
September 12 2017
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Woolwich, London, London, United Kingdom, SE18 4QH
2
GSK Investigational Site
Birmingham, Warwickshire, United Kingdom, B4 6DH
3
GSK Investigational Site
Birmingham, United Kingdom, WS2 9PS
4
GSK Investigational Site
London, United Kingdom, E1 1BB